CA2683756A1 - Method of treatment of age-related macular degeneration(amd) - Google Patents

Method of treatment of age-related macular degeneration(amd) Download PDF

Info

Publication number
CA2683756A1
CA2683756A1 CA002683756A CA2683756A CA2683756A1 CA 2683756 A1 CA2683756 A1 CA 2683756A1 CA 002683756 A CA002683756 A CA 002683756A CA 2683756 A CA2683756 A CA 2683756A CA 2683756 A1 CA2683756 A1 CA 2683756A1
Authority
CA
Canada
Prior art keywords
optionally substituted
cells
neuronal
subject
bas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002683756A
Other languages
English (en)
French (fr)
Inventor
Penelope Jane Huggins
Jack Gordon Parsons
Gaik Beng Kok
Vijaya Kenche
Mariana El Sous
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alterity Therapeutics Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA2711638A priority Critical patent/CA2711638C/en
Publication of CA2683756A1 publication Critical patent/CA2683756A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002683756A 2006-04-14 2007-04-13 Method of treatment of age-related macular degeneration(amd) Abandoned CA2683756A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2711638A CA2711638C (en) 2006-04-14 2007-04-13 3-substituted-8-hydroxypyridino[1,2-a]pyrimidin-4-one compounds and their use in treating retinal degenerative diseases

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79227806P 2006-04-14 2006-04-14
US60/792,278 2006-04-14
PCT/AU2007/000490 WO2007118276A1 (en) 2006-04-14 2007-04-13 Method of treatment of age-related macular degeneration(amd)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2711638A Division CA2711638C (en) 2006-04-14 2007-04-13 3-substituted-8-hydroxypyridino[1,2-a]pyrimidin-4-one compounds and their use in treating retinal degenerative diseases

Publications (1)

Publication Number Publication Date
CA2683756A1 true CA2683756A1 (en) 2007-10-25

Family

ID=38608967

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002683756A Abandoned CA2683756A1 (en) 2006-04-14 2007-04-13 Method of treatment of age-related macular degeneration(amd)

Country Status (14)

Country Link
US (3) US20100144693A1 (enExample)
EP (2) EP2514423A3 (enExample)
JP (1) JP5290147B2 (enExample)
KR (2) KR20100110396A (enExample)
CN (3) CN101987849B (enExample)
AU (2) AU2007240120A1 (enExample)
BR (2) BRPI0722382A2 (enExample)
CA (1) CA2683756A1 (enExample)
DK (1) DK2012789T3 (enExample)
ES (1) ES2437997T3 (enExample)
IL (1) IL207495A (enExample)
NZ (2) NZ590271A (enExample)
WO (1) WO2007118276A1 (enExample)
ZA (2) ZA200809493B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002950217A0 (en) 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
AU2006249866B2 (en) 2005-05-26 2011-10-13 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
JP5415942B2 (ja) * 2006-06-22 2014-02-12 プラナ バイオテクノロジー リミティッド 処置の方法およびその処置に有用な薬剤
CA2737219C (en) * 2008-08-11 2017-02-28 Tracy Keller Halofuginone analogs for inhibition of trna synthetases and uses thereof
WO2010071944A1 (en) * 2008-12-24 2010-07-01 Prana Biotechnology Limited Quinazolinone compounds
EP2389179A4 (en) 2009-01-26 2012-08-29 Michael Spino USE OF DEFERPRONE FOR THE TREATMENT AND PREVENTION OF IRON-RELATED EYE DISORDERS
CA2782015C (en) 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
WO2012122534A2 (en) 2011-03-10 2012-09-13 The Trustees Of Columbia University In The City Of New York N-quinolin-benzensulfonamides and related compounds for the treatment of cancer, autoimmune disorders and inflammation
CA2861840C (en) 2012-01-13 2020-12-15 President And Fellows Of Harvard College Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions
KR20150118106A (ko) 2012-12-20 2015-10-21 알데이라 테라퓨틱스, 아이엔씨. 페리-카르비놀
CN111135171B (zh) 2013-01-23 2023-09-08 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
AU2014209585A1 (en) 2013-01-25 2015-07-23 Aldeyra Therapeutics, Inc. Novel traps in the treatment of macular degeneration
EA031505B1 (ru) * 2014-12-02 2019-01-31 Прана Байотекнолоджи Лимитед СОЕДИНЕНИЯ 4Н-ПИРИДО[1,2-а]ПИРИМИДИН-4-ОНА
CN107533181B (zh) * 2015-04-29 2020-06-30 特里亚佩克斯有限公司 偏光膜、制备它的方法及包含它的偏光镜片
US10781178B2 (en) * 2015-08-12 2020-09-22 The General Hospital Corporation 8-hydroxyquinoline derivatives as diagnostic and therapeutic agents
CN118724806A (zh) 2015-08-21 2024-10-01 奥尔德拉医疗公司 氘化化合物和其用途
US11008290B2 (en) * 2015-09-24 2021-05-18 University Of Florida Research Foundation, Incorporated Halogenated quinoline derivatives as antimicrobial agents
CN109152774A (zh) 2016-05-09 2019-01-04 奥尔德拉医疗公司 眼部炎性病症和疾病的组合治疗
WO2018000047A1 (en) * 2016-07-01 2018-01-04 Prana Biotechnology Limited Method of treating immunoglobulin light chain amyloidosis
WO2018170476A1 (en) 2017-03-16 2018-09-20 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
CN111356451A (zh) 2017-10-10 2020-06-30 奥尔德拉医疗公司 炎性病症的治疗
WO2019237125A1 (en) 2018-06-08 2019-12-12 The General Hospital Corporation Inhibitors of prolyl-trna-synthetase
CN112714762A (zh) 2018-08-06 2021-04-27 奥尔德拉医疗公司 多晶型化合物及其用途
CN109232396B (zh) * 2018-11-27 2020-07-03 聊城大学 酰胺吡啶类衍生物及其用途
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CN113784954A (zh) 2019-05-02 2021-12-10 奥尔德拉医疗公司 多晶型化合物和其用途
WO2021231792A1 (en) 2020-05-13 2021-11-18 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
EP4175636A2 (en) * 2020-07-02 2023-05-10 The United States of America, as represented by the Secretary, Department of Health and Human Services Cyclic compounds for use in treating retinal degeneration
US12060334B2 (en) 2021-03-12 2024-08-13 University Of Florida Research Foundation, Incorporated 3-substituted phenazine derivatives as antimicrobial agents
CN113214249B (zh) * 2021-04-23 2023-09-19 成都大学 吡啶并[1,2-a]嘧啶-4-硫酮化合物的合成方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE505711A (enExample) 1950-09-09
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
HU178910B (en) * 1977-08-19 1982-07-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing 2,3-disubstituted-4-oxo-4h-pyrido/1,2-a/-pyrimidines
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
IT1204612B (it) 1987-05-14 1989-03-10 Bioresearch Spa Pteridine atte alla preparazione di composizioni farmaceutiche ad attivita' antiamnesica
US5314909A (en) * 1993-03-17 1994-05-24 Merck & Co., Inc. Use of non-steroidal antiiflammatory agents in macular degeneration
EP0693150B1 (de) 1993-04-08 1996-08-28 Ideal-Standard Gmbh Sanitäres wasserventil
US5631373A (en) 1993-11-05 1997-05-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
DE4418096A1 (de) * 1994-05-24 1995-11-30 Cassella Ag Verwendung von Pteridin-Derivaten als Hemmstoffe der NO-Synthase
US6168776B1 (en) 1994-07-19 2001-01-02 University Of Pittsburgh Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
US5801183A (en) 1995-01-27 1998-09-01 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists
PT959888E (pt) * 1996-08-13 2002-02-28 Gerolymatos P N Sa Utilizacao do agente quelante clioquinol para o fabrico de uma composicao farmaceutica para o tratamento de doenca de alzheimer
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
US5939421A (en) 1997-07-01 1999-08-17 Signal Pharmaceuticals, Inc. Quinazoline analogs and related compounds and methods for treating inflammatory conditions
US20020025944A1 (en) * 2000-04-28 2002-02-28 Bush Ashley I. Use of clioquinol for the therapy of Alzheimer's disease
US6337332B1 (en) * 1998-09-17 2002-01-08 Pfizer Inc. Neuropeptide Y receptor antagonists
EP1514867A3 (en) 1998-10-22 2005-03-23 NeuroSearch A/S Substituted phenyl derivatives, their preparation and use
US6369058B1 (en) * 1999-02-04 2002-04-09 New Millennium Pharmaceutical Research Inc. Brain delivery of folic acid for the prevention of alzheimer's disease and stroke
US6559160B1 (en) 1999-08-27 2003-05-06 Chemocentryx, Inc. Compounds and methods for modulating cxcr3 function
AUPR201600A0 (en) 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
BR0116493A (pt) 2000-12-21 2003-09-30 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase
FR2819187A1 (fr) * 2001-01-10 2002-07-12 Michel Xilinas Utilisation des substances chelatrices pour le traitement et la prevention de la deferrescence oculaire
EP1389209B1 (en) 2001-04-24 2009-04-08 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
FR2827599A1 (fr) * 2001-07-20 2003-01-24 Neuro3D Composes derives de quinoleine et quinoxaline,preparation et utilisations
JP2005504770A (ja) 2001-08-17 2005-02-17 メルク　エンド　カムパニー　インコーポレーテッド ５−スルホンアミド−８−ヒドロキシ−１，６−ナフチリジン−７−カルボキサミドの製造方法
WO2003070709A1 (en) 2002-02-20 2003-08-28 Ajinomoto Co.,Inc. Novel phenylalanine derivative
DE60336901D1 (de) 2002-03-07 2011-06-09 X Ceptor Therapeutics Inc Chinazolinon modulatoren von nukleinrezeptoren
AU2002950217A0 (en) * 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
AU2002951868A0 (en) * 2002-10-04 2002-10-24 Prana Biotechnology Limited Compound i
ES2440217T3 (es) * 2002-10-04 2014-01-28 Prana Biotechnology Limited Compuestos neurológicamente activos
EP1617844A4 (en) * 2003-04-03 2009-07-22 Prana Biotechnology Ltd TREATMENT OF NEUROLOGICAL DISEASES
AU2004249529A1 (en) * 2003-06-23 2004-12-29 Bellus Health (International) Limited Methods and compositions for treating amyloid-related diseases
DK1737831T3 (da) * 2004-04-02 2013-08-19 Prana Biotechnology Ltd Neurologisk aktive forbindelser
CA2593846A1 (en) * 2005-01-14 2006-08-10 The Regents Of The University Of California Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
WO2006117660A2 (en) * 2005-05-04 2006-11-09 Clio Pharmaceutical Corporation Method for treating cancer, coronary, inflammatory and macular disease, combining the modulation of zinc- and/or copper dependent proteins
JP5415942B2 (ja) * 2006-06-22 2014-02-12 プラナ バイオテクノロジー リミティッド 処置の方法およびその処置に有用な薬剤

Also Published As

Publication number Publication date
AU2007240120A2 (en) 2008-12-18
IL207495A (en) 2015-05-31
DK2012789T3 (da) 2013-12-16
AU2010206074A1 (en) 2010-08-19
IL207495A0 (en) 2010-12-30
ZA201005922B (en) 2013-09-25
WO2007118276A1 (en) 2007-10-25
EP2514423A3 (en) 2012-12-19
AU2010206074B2 (en) 2012-08-30
NZ572591A (en) 2012-01-12
ES2437997T3 (es) 2014-01-15
US20140088122A1 (en) 2014-03-27
NZ590271A (en) 2011-12-22
EP2012789B1 (en) 2013-09-25
AU2007240120A1 (en) 2007-10-25
US20100144693A1 (en) 2010-06-10
JP2009533356A (ja) 2009-09-17
ZA200809493B (en) 2010-08-25
KR20080109096A (ko) 2008-12-16
US20110071167A1 (en) 2011-03-24
EP2514423A2 (en) 2012-10-24
EP2012789A4 (en) 2011-02-16
EP2012789A1 (en) 2009-01-14
US9163018B2 (en) 2015-10-20
CN102225930A (zh) 2011-10-26
BRPI0722382A2 (pt) 2012-06-05
KR20100110396A (ko) 2010-10-12
CN101987849B (zh) 2013-05-08
CN101534826A (zh) 2009-09-16
CN101987849A (zh) 2011-03-23
JP5290147B2 (ja) 2013-09-18
BRPI0710737A2 (pt) 2011-05-10

Similar Documents

Publication Publication Date Title
US9163018B2 (en) Method of treatment of age-related macular degeneration (AMD)
US7692011B2 (en) 8-hydroxy and 8-mercapto quinazolinones
KR101149323B1 (ko) 8-하이드록시 퀴놀린 유도체
JP2024509265A (ja) 赤血球増加症を処置するための組成物および方法
CA2711638C (en) 3-substituted-8-hydroxypyridino[1,2-a]pyrimidin-4-one compounds and their use in treating retinal degenerative diseases
CN1720238B (zh) 神经活性化合物
KR102069395B1 (ko) 제i형 및 제ii형 당뇨병의 치료
SK69699A3 (en) 2-imidazolinylaminoindazole compounds useful as alpha-2 adrenoceptor agonists
US20260130898A1 (en) Aminonaphthoquinone compounds for treatment and/or prevention of optic neuropathy
US20240024332A1 (en) Apilimod compositions and methods of use
AU2003265740B8 (en) Neurologically-active compounds
US20120022097A1 (en) Compositions and Methods for Treating Cancer
AU2024316559A1 (en) Apilimod compositions and methods of use
JPH05140158A (ja) 緑内障の治療に有用な置換ピリジン誘導体
US8975274B2 (en) Compositions and methods for treating cancer
KR20070018928A (ko) 신경 활성 화합물

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130823